Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) obtained a drug registration certificate for its Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution from China's National Medical Products Administration.
The drug is used for the treatment of acute and chronic respiratory diseases caused by cough, viscous sputum, difficult sputum excretion, and wheezing, among other things, according to a Monday Hong Kong bourse filing.